Membership Directory
ArQule, Inc.
Category: Drug Development
Phone: +1 (781) 994-0300
Fax: +1 (781) 376-6019
Website: http://www.arqule.com
Location: Woburn, MA
ArQule is a clinical stage biotechnology company engaged in the development of innovative cancer therapies directed toward molecular targets that play critical roles in the development of human cancers. The Company’s mission is to discover and develop novel products that target multiple tumor types, act selectively against cancer cells and are well tolerated by patients. Its products and research programs are based on an understanding of biological processes that lead to the proliferation and metastasis of cancer cells, combined with an ability to generate product candidates possessing pre-selected, drug-like properties and designed to act with specificity against cancer cells. These qualities, when present from the earliest stages of product development, are believed to increase the likelihood of producing safe, effective and marketable drugs. ArQule believes that its combined expertise in cancer biology and chemistry differentiates it from many companies at a similar stage of development.
The Company’s lead product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is currently being evaluated in the clinic as monotherapy and in combination therapy. ArQule has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. in the U.S., Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where commercial rights have been licensed to Kyowa Hakko Kirin Co., Ltd. ArQule’s product pipeline offers the potential for multiple therapeutic candidates based on diverse biological targets, mechanisms of action and chemistry. The pipeline includes of inhibitors of the Eg5 kinesin spindle protein and the BRAF kinase, as well as activators of the cell’s DNA damage response mechanism mediated by the E2F-1 transcription factor. The Company’s drug discovery efforts are focused primarily on the ArQule Kinase Inhibitor Platform (“AKIP™”), employed to generate a new class of compounds designed to inhibit a variety of kinases potently, selectively and without competing with adenosine triphosphate.
